CIK 0001287098 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MAXCYTE, INC.
Sign in to watch- Ticker
- MXCT
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522210438
- Phone
- 301-517-5556
- Business address
- 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
- Former names
- MAXCYTE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 42 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-26 | Johnston John Joseph Director | Sale 10b5-1 | −5,000 | $4.41 | $22K | 120,583 |
| 2024-03-26 | Johnston John Joseph Director | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 617 | ||
| 2024-03-15 | Ross Thomas M. EVP, GLOBAL SALES & MARKETING | Grant or award | +25,000 | 25,000 | ||
| 2024-03-15 | Ross Thomas M. EVP, GLOBAL SALES & MARKETING | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-03-15 | Sandoval David I. GENERAL COUNSEL | Grant or award | +3,913 | 45,913 | ||
| 2024-03-15 | Sandoval David I. GENERAL COUNSEL | Grant or award · Employee Stock Option (right to buy) | +15,625 | 15,625 | ||
| 2024-03-15 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Grant or award | +81,250 | 81,250 | ||
| 2024-03-15 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2024-02-26 | Johnston John Joseph Director | Option exercise 10b5-1 | +5,000 | $2.14 | $11K | 125,583 |
| 2024-02-26 | Johnston John Joseph Director | Sale 10b5-1 | −5,000 | $4.60 | $23K | 120,583 |
| 2024-02-26 | Johnston John Joseph Director | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 5,617 | ||
| 2024-01-26 | Johnston John Joseph Director | Option exercise 10b5-1 | +5,000 | $2.14 | $11K | 125,583 |
| 2024-01-26 | Johnston John Joseph Director | Sale 10b5-1 | −5,000 | $5.12 | $26K | 120,583 |
| 2024-01-26 | Johnston John Joseph Director | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 10,617 | ||
| 2024-01-03 | Masoud Maher President and CEO | Grant or award · Employee Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2023-12-26 | Johnston John Joseph Director | Option exercise 10b5-1 | +5,000 | $2.14 | $11K | 125,583 |
| 2023-12-26 | Johnston John Joseph Director | Sale 10b5-1 | −5,000 | $4.53 | $23K | 120,583 |
| 2023-12-26 | Johnston John Joseph Director | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 15,617 | ||
| 2023-12-05 | Doerfler Douglas President and CEO | Option exercise | +99,442 | $0.04 | $4K | 432,639 |
| 2023-12-05 | Doerfler Douglas President and CEO | Sale | −99,442 | $5.17 | $514K | 333,197 |
Page 8 of 15 · 282 trades